Welcome to our dedicated page for Quest Diagnostics SEC filings (Ticker: DGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quest Diagnostics Incorporated (NYSE: DGX) files reports with the U.S. Securities and Exchange Commission that provide formal insight into its operations as a medical laboratories company focused on diagnostic testing and diagnostic information services. On this page, investors can review Quest Diagnostics’ SEC filings alongside AI-powered tools that help explain the content and context of these documents.
Quest Diagnostics uses current reports on Form 8-K to disclose material events such as quarterly financial results and investor presentations. For example, the company has filed 8-Ks to announce results for specific quarters and to furnish presentation materials used at the J.P. Morgan Healthcare Conference, covering topics such as strategy, performance and market developments. These filings give investors structured access to information that the company shares with the market.
In addition to 8-Ks, users can expect to find Quest Diagnostics’ periodic reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain detailed discussions of business segments, risk factors and financial condition. While these specific forms are not reproduced in the provided data, they are standard components of a public company’s SEC reporting and are accessible through this filings page.
The platform enhances these documents with AI-generated summaries that highlight key points, helping users navigate complex language and lengthy sections. For instance, AI tools can surface main themes from a 10-K, summarize quarterly performance from a 10-Q or clarify the significance of information furnished in an 8-K. Real-time updates from the SEC’s EDGAR system ensure that new filings appear promptly.
Investors interested in governance, capital allocation and executive communications can use this page to monitor Quest Diagnostics’ regulatory disclosures, while AI assistance streamlines the process of reviewing and interpreting the company’s filings.
Quest Diagnostics (DGX) reported an insider transaction by its SVP for Diagnostic Services. On 10/21/2025, the officer acquired 46 shares of common stock at $189.079, as noted in a footnote describing purchases via a dividend reinvestment plan eligible for deferred reporting under Rule 16a-6 but reported early. Following this, direct beneficial ownership stood at 15,333 shares.
Quest Diagnostics (DGX): A company officer reported an insider transaction on a Form 4. On 10/21/2025, the SVP, Clinical Solutions acquired 15 shares of common stock at $189.076 per share.
Following this transaction, the reporting person beneficially owns 8,379 shares directly, plus 358 shares indirectly through a trust and 1,635 shares indirectly via the Company’s 401(k) plan.
Per the footnotes, the 15 shares were acquired through a dividend reinvestment plan and are eligible for deferred reporting on Form 5 under Rule 16a-6; the reporting person chose to report them early.
Quest Diagnostics (DGX) director Gary M. Pfeiffer reported a sale of common stock. On 10/22/2025, he sold 1,482 shares at $182.40 per share, and reported 29,431 shares beneficially owned directly after the transaction.
The filing also records an intra-plan transfer on 10/23/2025 within the company’s Amended and Restated Deferred Compensation Plan for Directors. 4,413.284 phantom common stock units—payable in cash and representing an equivalent number of shares—were transferred from the company stock fund to another investment option at a listed price of $190.58.
Quest Diagnostics (DGX) reported an insider transaction by a director. On 10/21/2025, the director acquired 70 shares of common stock at $189.082 per share, as disclosed on a Form 4.
The filing states the shares were acquired through a dividend reinvestment plan administered by the broker and were eligible for deferred reporting on Form 5 under Rule 16a-6; the reporting person chose to report early here. Following the transaction, the director beneficially owns 18,287 shares, held directly.
Quest Diagnostics (DGX) reported an insider transaction on Form 4. SVP & Chief Commercial Officer Mark E. Delaney acquired 15 shares of common stock on 10/21/2025 at $189.077 per share via a dividend reinvestment plan. Following the transaction, he beneficially owns 7,530 shares, held directly. The filing notes the transaction is eligible for deferred reporting under Rule 16a-6 and was reported early.
Quest Diagnostics (DGX) director Robert B. Carter reported acquiring 6 shares of common stock on 10/21/2025 at $189.089 per share. The shares were obtained through a dividend reinvestment plan eligible for deferred reporting on Form 5 under Rule 16a-6; the transaction was reported early.
After this transaction, Carter beneficially owns 2,698 shares, held directly.
DGX filed a Form 144 notice for a proposed sale of 1,482 common shares through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $270,316.80. The approximate sale date is October 22, 2025.
The shares were acquired via restricted stock vesting from the issuer on May 16, 2025 as compensation. As context, 111,242,362 shares were outstanding.
Quest Diagnostics (DGX) filed an 8‑K stating it issued a press release announcing its results for the quarter ended September 30, 2025. The company furnished the press release as Exhibit 99.1, dated October 21, 2025.
The filing falls under Item 2.02 (Results of Operations and Financial Condition). Quest Diagnostics’ common stock trades on the NYSE under the symbol DGX.
Quest Diagnostics (DGX) reported higher Q3 2025 results. Net revenues rose to $2,816 million from $2,488 million a year ago, and diluted EPS increased to $2.16 from $1.99. Operating income grew to $386 million, while net income attributable to Quest reached $245 million. Cost of services and SG&A increased alongside revenue growth, and Q3 included $11 million of restructuring and impairment charges.
For the first nine months of 2025, revenue was $8,229 million and diluted EPS was $6.57. Operating cash flow was strong at $1,421 million, funding $369 million of capex, $263 million of dividends, and $150 million of share repurchases (0.9 million shares). Cash ended at $432 million; total assets were $16,197 million and stockholders’ equity was $7,295 million.
DGX repaid $600 million notes that matured in March 2025 and extended its $750 million revolver to April 2030, with a $500 million accordion. The company closed the purchase of select Spectra Laboratories clinical testing assets for $34 million and finalized LifeLabs purchase accounting. As of October 15, 2025, shares outstanding were 111,242,362.
Director Timothy M. Ring reported a non‑derivative change related to deferred compensation in Quest Diagnostics (DGX). On 10/01/2025 he received an accrual of 233 phantom stock units under the company’s Amended and Restated Deferred Compensation Plan for Directors; these units convert to cash payable upon his termination of service as a director. The filing shows 17,036.495 phantom stock units credited in his deferred compensation account as of the transaction date, which includes units from dividend reinvestment transactions exempt from reporting. The Form 4 was signed by an attorney‑in‑fact on 10/03/2025. No option exercises, cash purchases, or sales of common stock are reported in this filing.